XERS (Xeris Biopharma Holdings, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by XERS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-21 | John Patrick Jr Shannon | See Remarks | F | — | — |
| 2026-08-21 | Kevin McCulloch | See Remarks | F | — | — |
| 2026-08-12 | Steven Pieper | See Remarks | Sell | — | — |
| 2026-08-04 | Kevin McCulloch | See Remarks | Sell | — | — |
| 2026-08-04 | Beth Hecht | See Remarks | Sell | — | — |
| 2026-07-07 | Steven Pieper | See Remarks | Sell | — | — |
| 2026-07-02 | Kevin McCulloch | See Remarks | Sell | — | — |
| 2026-07-02 | NERISSA KREHER | Director | A | — | — |
| 2026-07-02 | Beth Hecht | See Remarks | Sell | — | — |
| 2026-06-05 | JOHN JOHNSON | Director | MIXED | — | — |
| 2026-06-05 | James Aloysius Brady | Director | A | — | — |
| 2026-06-05 | BARBARA-JEAN ANNE BORMANN-KENNEDY | Director | MIXED | — | — |
| 2026-06-05 | MARLA PERSKY | Director | MIXED | — | — |
| 2026-06-05 | Garheng Kong | Director | A | — | — |
| 2026-06-05 | DAWN HALKUFF | Director | MIXED | — | — |
| 2026-06-02 | Beth Hecht | See Remarks | Sell | — | — |
| 2026-05-01 | Beth Hecht | See Remarks | Sell | — | — |
| 2026-04-03 | Beth Hecht | See Remarks | Sell | — | — |
| 2026-04-01 | James Aloysius Brady | Director | Sell | — | — |
| 2026-03-16 | Kevin McCulloch | See Remarks | M | — | — |
| 2026-03-05 | Steven Pieper | See Remarks | M | — | — |
| 2026-03-04 | Beth Hecht | See Remarks | Sell | — | — |
| 2026-02-25 | Anh Tu Nguyen | See Remarks | F | — | — |
| 2026-02-02 | Anh Tu Nguyen | See Remarks | A | — | — |
| 2026-02-02 | Kevin McCulloch | See Remarks | MIXED | — | — |
| 2026-02-02 | Steven Pieper | See Remarks | MIXED | — | — |
| 2026-02-02 | John Patrick Jr Shannon | See Remarks | MIXED | — | — |
| 2026-02-02 | Beth Hecht | See Remarks | MIXED | — | — |
| 2026-01-09 | Kevin McCulloch | See Remarks | Sell | — | — |
| 2026-01-06 | John Patrick Jr Shannon | See Remarks | MIXED | — | — |
| 2026-01-05 | Beth Hecht | See Remarks | Sell | — | — |
| 2025-12-19 | JOHN JOHNSON | Director | Sell | — | — |
| 2025-12-15 | BARBARA-JEAN ANNE BORMANN-KENNEDY | Director | Sell | — | — |
| 2025-12-02 | Beth Hecht | See Remarks | Sell | — | — |
| 2025-11-17 | John Patrick Jr Shannon | See Remarks | MIXED | — | — |
| 2025-11-13 | Beth Hecht | See Remarks | Sell | — | — |
| 2025-10-03 | Kevin McCulloch | See Remarks | F | — | — |
| 2025-09-15 | Kevin McCulloch | See Remarks | J | — | — |
| 2025-09-12 | MARLA PERSKY | Director | Sell | — | — |
| 2025-08-29 | JEFFREY W SHERMAN | Director | MIXED | — | — |
| 2025-08-15 | JOHN JOHNSON | Director | Sell | — | — |
| 2025-08-13 | DAWN HALKUFF | Director | Sell | — | — |
| 2025-08-04 | Kevin McCulloch | See Remarks | F | — | — |
| 2025-08-04 | John Patrick Jr Shannon | See Remarks | F | — | — |
| 2025-06-16 | Kevin McCulloch | See Remarks | Buy | — | — |
| 2025-06-04 | JEFFREY W SHERMAN | Director | A | — | — |
| 2025-06-04 | Garheng Kong | Director | A | — | — |
| 2025-06-04 | JOHN JOHNSON | Director | A | — | — |
| 2025-06-04 | DAWN HALKUFF | Director | A | — | — |
| 2025-06-04 | BARBARA-JEAN ANNE BORMANN-KENNEDY | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | See Remarks | 3,821,494 | — |
| — | 10%+ Owner | 3,000,642 | — |
| — | See Remarks | 2,898,933 | — |
| — | See Remarks | 1,679,208 | — |
| — | See Remarks | 1,361,053 | — |
| — | See Remarks | 1,144,462 | — |
| — | 10%+ Owner | 930,383 | — |
| — | 10%+ Owner | 878,518 | — |
| — | 10%+ Owner | 874,333 | — |
| — | 10%+ Owner | 873,520 | — |
| — | 10%+ Owner | 857,821 | — |
| — | Chief Scientific Officer | 719,780 | — |
| — | Director | 683,083 | — |
| — | See Remarks | 398,733 | — |
| — | See Remarks | 346,288 | — |
| — | Director | 266,820 | — |
| — | Director | 238,337 | — |
| — | See Remarks | 208,090 | — |
| — | Director | 157,063 | — |
| — | Director | 150,693 | — |
| — | Director | 138,359 | — |
| — | Director | 135,000 | — |
| — | Director | 124,603 | — |
| — | Director | 113,359 | — |
| — | Director | 33,582 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XERS quote page; the site-wide leaderboard is on the insider transactions hub.